Navigation Links
Inspire Announces Presentations at 2007 Association for Research in,Vision and Ophthalmology Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists and collaborators related to Inspire will present information from five abstracts at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 6-10, 2007 in Ft. Lauderdale, Florida. These abstracts, which will be presented in poster sessions, are related to three of Inspire's programs, including bacterial conjunctivitis, dry eye and allergy.

Two poster presentations are related to AzaSite(TM) (azithromycin ophthalmic solution) 1%, a treatment for bacterial conjunctivitis, which was recently approved by the U.S. Food and Drug Administration.

-- Development of a Commercial Eye Drop Formulation of Azithromycin

L.M. Bowman, E. Si, J. Pang, M. Friedlaender

Sunday, May 6, 2007, 2:30 p.m. - 4:15 p.m.

-- Frequent Dosing With Topical 1% Azithromycin is Effective in Reducing Azithromycin-Resistant Pseudomonas aeruginosa Colony Counts in a NZW Rabbit Model

K.A. Yates, E.G. Romanowski, R.P. Kowalski, F.S. Mah, Y.J. Gordon

Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

Three poster presentations are related to Inspire's development programs in dry eye disease and allergies.

-- Effect of Diquafosol on Ocular Surface Health in Dry Eye Disease

R. Brazzell, D.J. Kellerman, A. Schaberg, B.Yerxa, T. Durham

Sunday, May 6, 2007, 11:00 a.m. - 12:45 p.m.

-- A Correlation Between Central Corneal Staining and Visual Function in Patients Diagnosed With Dry Eye

G.W. Ousler, III, K. Brazzell, T. Durham, P. Walker, R.T. Anderson, M.B. Abelson

Sunday, May 6, 2007, 11:00 a.m. - 12:45 p.m.

-- The Pharmacological Properties of Epinastine on Histamine H2 and H4 Receptors

S.C. Wolff, K. Brubaker, R.C. Wright, J.L. Boyer

Monday, May 7, 2007, 3:00 p.m. - 4:45 p.m.

These po
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Presentations at Two European Scientific Conferences
3. Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

Post Your Comments:
(Date:11/7/2009)... BEACH, Fla., Nov. 7 Patients repo... an effective therapy in treating acute swelling a...rious genetic disorder, according to data presente...sthma & Immunology (ACAAI) Annual Meeting. The...nts conducted in parallel with the ongoing, prospe...
(Date:11/6/2009)...LL, Wash., Nov. 6 SCOLR ...l results for the three and nine months ended Sept...harma,s President and CEO, said, "We continue to a...r ibuprofen formulation. Several potential partner...rsonnel and external resources as they evaluate th...
(Date:11/6/2009)...OUIS, Nov. 6 Recession i...depress sales for Allied Healthcare Products in th...er 30, 2009. ,, Sales declines pushed Allied in...uarter was about $745,000, or negative 9 cents per...of about $208,000, or 3 cents per share. ,, Sa...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6Discovering soybean plants resistant to aphids and a new aphid 9530 1Discovering soybean plants resistant to aphids and a new aphid 9530 2Discovering soybean plants resistant to aphids and a new aphid 9530 3Discovering soybean plants resistant to aphids and a new aphid 9530 4PLUS Diagnostics Announces Senior Executive Appointments 54089 1PLUS Diagnostics Announces Senior Executive Appointments 54089 2PLUS Diagnostics Announces Senior Executive Appointments 54089 3Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin 28TM 29 54086 1Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin 28TM 29 54086 2Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin 28TM 29 54086 3
... (Zurich), Switzerland, May 24, 2007 - Cytos,Biote... a,placebo-controlled, double-blind combined phase...ndidate for the treatment of,psoriasis and other i...rst-time-in-man clinical trial and included 48 pat...riasis. In a first part,of the study, the safety a...
... Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen,...that develops targeted,anticancer therapeutics usi...oday announced that clinical findings for three,di...umors are to be,reported at the 43rd American Soci...take place June 1-5, 2007 in Chicago, IL., Trastuz...
Other Medicine Technology:Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 2Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 3Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 4ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 2ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO 3
(Date:11/8/2009)...SHINGTON, Nov. 8 The fo...tor, Operation Rescue Insurrecta Nex. ,, Mr. T...ve been fighting to keep child-killing by abortion... Terry states: "This is a great first step to vict...have a lot of fighting ahead of us. Our rejoicing ...
(Date:11/8/2009)...LLYWOOD, Calif., Nov. 8 ...on of Babies luncheon to recognize prominent indiv...dren and who are role models for March of Dimes co... of the March of Dimes November Prematurity Awaren... were urged to join the fight for preemies! ,, ...
(Date:11/7/2009)...USTON, Nov. 7 The Ameri...sa James, Director of Health at the Family Violenc...shed Service today at its semi-annual policy-makin... is the highest honor the AMA House of Delegates b...//www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ...
(Date:11/7/2009)...SHINGTON, Nov. 7 With t...antichoice extremists are holding the entire bill ... are demanding that the bill go far beyond the sta...orporated into the original bill. In an outrageou...y Saturday afternoon, antichoice Democrats are dem...
(Date:11/7/2009)...ON, Nov. 7 Americans United for Life Action endor...pak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smi... money from going to abortion in health care refor... and CEO Dr. Charmaine Yoest said, "Americans Unit...lsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Ame...
Breaking Medicine News(10 mins):Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:AMA Honors Family Violence Prevention Expert 2Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2
...rchers at the Monash Institute of Medical Research...nfrared spectroscopy, which allowed scientists// t... it was the first of its kind in Australia, helped...esearch (MIMR) are carrying out studies to underst...
...tists at the University of Bristol have recommende...epaired by bioengineered tissue implants //without...e maturation of cartilage implanted with engineere...ered cartilage implanted in injured and osteoarthr...
...ar-old Indian boy, Santosh Baniya whose parents we...e of the stigma associated with the disease//. ...fter he set himself on fire in Ahmedabad last week...urviving his parents as well as being ostracised o...
...ding to a research conducted by Stephanie Chiuve i...educes the risk of heart ailments//. U.S. rese...pressure and cholesterol can benefit if they alter...nking and smoking habits. But it is good news ...
...ew Zealand Winegrowers are affected by the type 3 ...and quality of grapevines//. But most of the w...ine which are tested vines and are free from the v...d ongoing management and detection. Mr Manson said...
...yers in British Columbia (B.C) are bearing the med... the province for health services//. Government o...lem. Health Minister, George Abbott of B.C. ...is prompting health authorities to look at novel w...
Other Medicine News:Health News:Preterm Babies Benefited from a New NI Spectroscopy 2Health News:Engineered Tissue Implants benefited Knee Injured patients 2
Agarose, ultra high resolution, Molecular Biology Grade
AGAROSE I (Molecular Biology Grade)
Agarose, 500g
Agarose NA
Medicine Products: